The company's revenues were $186.5 million in the fourth quarter and $753.8 million for fiscal year 2016.
Last month, the foundation, in partnership with the Washington State Department of Health, released seven educational videos about prenatal testing.
The firm aims to compete initially in the hereditary cancer screening market by better identifying patients who qualify for genetic testing.
Geisinger Health System's MyCode Community Health Initiative has signed up more than 100,000 participants and has returned results to about 100 patients.
Over the last half year, CeGaT lowered turnaround times and prices for its assays, and its lab recently passed CAP inspection.
Ranomics is building a business around providing functional data on variants of unknown significance, starting with BRCA1 mutations.
Myriad reported revenues of $193.3 million, beating analysts' consensus estimates.
The researchers looked at the first 10,030 consecutive patients referred to GeneDx for germline hereditary cancer panel testing by next-generation sequencing.
The company billed more than 5,100 reports during the third quarter, a 360 percent increase compared to the year-ago period, and accessioned more than 5,400 samples.
The company beat consensus Wall Street estimates for the quarter, reporting revenues of $183.5 million.
The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.
The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.
New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.
In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.